论文部分内容阅读
背景与目的:雄激素受体(androgen receptor,AR)辅助因子失调将激活AR并直接促进前列腺癌的发生、发展。Zimp7(human zinc finger-containing,Miz1,PIAS-like protein on chromosome 7)是一新发现的AR辅助因子,本研究的前期工作证实,其在中国前列腺癌组织标本中高表达,预示着其可能是前列腺癌的一种特异性标志物。本研究旨在探讨尿液中Zimp7在前列腺癌早期诊断中的应用价值。方法:收集97例患者的尿液标本,其中42例前列腺癌患者,50例前列腺良性病变患者,5例膀胱癌患者。采用实时荧光定量PCR技术(real-time quantitative polymerase chain reaction,RT-PCR)检测Zimp7 mRNA的表达。结果:当前列腺特异抗原(prostate specific antigen,PSA)为4~10 ng/mL时Zimp7的受试者工作特征曲线下面积(AUC)为0.850(P=0.002),Zimp7阈值设定为53.00时其诊断前列腺癌的灵敏度、特异度、阳性预测值、阴性预测值分别为77.8%、84.6%、63.6%和91.7%;当不进行PSA分层时,Zimp7的AUC值为0.684(P=0.004);当阈值设定为17.26时,其灵敏度、特异度、阳性预测值、阴性预测值分别为66.7%、63.0%、60.5%和69.0%。另外,未发现Zimp7与年龄、PSA值和Gleason值之间有显著相关性。结论:检测尿液中Zimp7 mRNA是一种无创的、可行的前列腺癌早期诊断方法。
BACKGROUND & AIM: Disorders of the androgen receptor (AR) cofactors activate AR and directly promote the development and progression of prostate cancer. Zimp7 (human zinc finger-containing, Miz1, PIAS-like protein 7) is a newly discovered AR cofactor. The preliminary work of this study confirmed that it is highly expressed in Chinese prostate cancer tissue specimens, indicating that it may be the prostate A specific marker of cancer. This study aimed to explore the value of urine Zimp7 in the early diagnosis of prostate cancer. METHODS: Urine specimens from 97 patients were collected, including 42 prostate cancer patients, 50 benign prostatic hyperplasia patients and 5 bladder cancer patients. Zimp7 mRNA expression was detected by real-time quantitative polymerase chain reaction (RT-PCR). Results: The area under the working characteristic curve (AUC) of Zimp7 was 0.850 (P = 0.002) when the prostate specific antigen (PSA) was 4 ~ 10 ng / mL and the threshold of Zimp7 was 53.00 The sensitivity, specificity, positive predictive value and negative predictive value of Zimp7 were 77.8%, 84.6%, 63.6% and 91.7% respectively. The AUC of Zimp7 was 0.684 (P = 0.004) when PSA stratification was not performed. When the threshold was set to 17.26, the sensitivity, specificity, positive predictive value and negative predictive value were 66.7%, 63.0%, 60.5% and 69.0% respectively. In addition, no significant correlation between Zimp7 and age, PSA value, and Gleason value was found. Conclusion: Detecting Zimp7 mRNA in urine is a noninvasive and feasible method for early diagnosis of prostate cancer.